AP2011005843A0 - Use of deferiprone for treatment and prevention ofiron-related eye disorders. - Google Patents

Use of deferiprone for treatment and prevention ofiron-related eye disorders.

Info

Publication number
AP2011005843A0
AP2011005843A0 AP2011005843A AP2011005843A AP2011005843A0 AP 2011005843 A0 AP2011005843 A0 AP 2011005843A0 AP 2011005843 A AP2011005843 A AP 2011005843A AP 2011005843 A AP2011005843 A AP 2011005843A AP 2011005843 A0 AP2011005843 A0 AP 2011005843A0
Authority
AP
ARIPO
Prior art keywords
ofiron
deferiprone
prevention
treatment
eye disorders
Prior art date
Application number
AP2011005843A
Other languages
English (en)
Inventor
Joshua Lawrence Dunaief
Original Assignee
Joshua Lawrence Dunaief
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joshua Lawrence Dunaief filed Critical Joshua Lawrence Dunaief
Publication of AP2011005843A0 publication Critical patent/AP2011005843A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AP2011005843A 2009-01-26 2009-11-12 Use of deferiprone for treatment and prevention ofiron-related eye disorders. AP2011005843A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14724509P 2009-01-26 2009-01-26
PCT/CA2009/001639 WO2010083582A1 (en) 2009-01-26 2009-11-12 Use of deferiprone for treatment and prevention of iron-related eye disorders

Publications (1)

Publication Number Publication Date
AP2011005843A0 true AP2011005843A0 (en) 2011-08-31

Family

ID=42355449

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2011005843A AP2011005843A0 (en) 2009-01-26 2009-11-12 Use of deferiprone for treatment and prevention ofiron-related eye disorders.

Country Status (24)

Country Link
US (1) US20130023569A1 (enExample)
EP (1) EP2389179A4 (enExample)
JP (1) JP5604631B2 (enExample)
KR (1) KR20120078667A (enExample)
CN (1) CN102348456A (enExample)
AP (1) AP2011005843A0 (enExample)
AU (1) AU2009338093B2 (enExample)
BR (1) BRPI0920492A2 (enExample)
CA (1) CA2750599A1 (enExample)
CL (1) CL2011001812A1 (enExample)
CR (1) CR20110456A (enExample)
EA (1) EA201170970A1 (enExample)
IL (1) IL214291A (enExample)
MA (1) MA33090B1 (enExample)
MX (1) MX2011007947A (enExample)
MY (1) MY161269A (enExample)
NI (1) NI201100148A (enExample)
NZ (1) NZ594728A (enExample)
PE (1) PE20120515A1 (enExample)
SG (1) SG173145A1 (enExample)
TN (1) TN2011000366A1 (enExample)
UA (1) UA103366C2 (enExample)
WO (1) WO2010083582A1 (enExample)
ZA (1) ZA201105514B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016205030B2 (en) * 2015-01-09 2021-04-01 The Board Of Trustees Of The University Of Illinois Restoring physiology in iron-deficient organisms using small molecules
CN111918646B (zh) 2017-10-25 2022-02-22 奇斯药制品公司 延迟释放去铁酮片剂及其使用方法
US12016851B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
US12016850B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046219A (en) * 1995-01-20 2000-04-04 Cornell Research Foundation, Inc. Method for the treatment of conditions mediated by collagen formation together with cell proliferation by application of inhibitors of protein hydroxylation
US5674888A (en) * 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
AUPQ262499A0 (en) * 1999-09-02 1999-09-23 University Of Queensland, The Novel iron chelators
WO2004041151A2 (en) * 2002-11-07 2004-05-21 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
EP1601367A2 (en) * 2003-02-06 2005-12-07 Bioresponse L.L.C. The combined use of cruciferous indoles and chelators for the treatment of papillomavirus-related conditions
DK1991225T3 (da) * 2006-02-22 2013-12-16 Apotex Technologies Inc Anvendelse af deferipron og fremgangsmåder til at behandle og/eller forebygge Friedreichs ataksi, der resulterer af intracellulær fejlhåndtering af jern
JP5290147B2 (ja) 2006-04-14 2013-09-18 プラナ バイオテクノロジー リミティッド 加齢黄斑変性症（ａｍｄ）の処置方法
ITMI20061770A1 (it) * 2006-09-18 2008-03-19 Carlo Ghisalberti Metodo cosmetico di riduzione delle occhiaie
US8501789B2 (en) * 2007-01-19 2013-08-06 The Trustees Of The University Of Pennsylvania Use of salicylaldehyde isonicotinoyl hydrazone (SIH) for protection against retinal disease

Also Published As

Publication number Publication date
EA201170970A1 (ru) 2012-03-30
MA33090B1 (fr) 2012-03-01
NI201100148A (es) 2012-03-06
BRPI0920492A2 (pt) 2019-07-09
UA103366C2 (ru) 2013-10-10
AU2009338093A1 (en) 2011-09-08
JP5604631B2 (ja) 2014-10-08
EP2389179A1 (en) 2011-11-30
AU2009338093B2 (en) 2014-08-28
JP2012515725A (ja) 2012-07-12
MY161269A (en) 2017-04-14
TN2011000366A1 (en) 2013-03-27
EP2389179A4 (en) 2012-08-29
SG173145A1 (en) 2011-08-29
MX2011007947A (es) 2011-12-14
NZ594728A (en) 2013-03-28
CR20110456A (es) 2012-05-31
PE20120515A1 (es) 2012-05-20
WO2010083582A1 (en) 2010-07-29
IL214291A (en) 2015-03-31
CA2750599A1 (en) 2010-07-29
US20130023569A1 (en) 2013-01-24
IL214291A0 (en) 2011-09-27
CL2011001812A1 (es) 2012-02-03
CN102348456A (zh) 2012-02-08
KR20120078667A (ko) 2012-07-10
ZA201105514B (en) 2012-10-31

Similar Documents

Publication Publication Date Title
SI2467372T1 (sl) Zdravljenje motenj, povezanih z BDNF, z uporabo lakvinimoda
ZA201402615B (en) Prevention and treatment of ocular conditions
ZA201108586B (en) Combination of a tnf-alpha antagonist and a vegf antagonist for use in the treatment or prevention of diseases of the eye
IL217768A0 (en) Treatment of crohn's disease with laquinimod
WO2011071995A9 (en) Compounds and methods of treating ocular disorders
ZA201202596B (en) Compounds for the treatment of dyslipidemia and related diseases
PL2701645T3 (pl) Urządzenie do leczenia i/lub zapobiegania chorobom rogówki
PT2427193T (pt) Utilização de inibidores da pde7 para o tratamento de distúrbios do movimento
IL218143A0 (en) Substituted heterocyclic derivatives for the treatment of pain and epilepsy
PL2524693T3 (pl) Farmaceutyk do zapobiegania lub leczenia chorób, którym towarzyszy angiogeneza tkanki oka i/lub zwiększona przepuszczalność naczyń krwionośnych oka
ZA201106076B (en) Treatment of insulin-resistant disorders
IL225896A0 (en) Treatment of mecp-2 related disorders
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
IL215990A0 (en) Phosphotetrahydfropyran compounds for the treatment of wounds and fibrotic disorders
AP2011005843A0 (en) Use of deferiprone for treatment and prevention ofiron-related eye disorders.
IL223219A0 (en) Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies
EP2459507A4 (en) USE OF ERYTHRITOL FOR THE PREVENTION OR TREATMENT OF HYPERTONIA
EP2531186A4 (en) TREATMENT OF HAIR DRESSES
GB0814043D0 (en) The treatment of skin disorders
ZA201304121B (en) Arlysulfonamide derivatives for the prevention or treatment of specific ophthalmologic disorders
IL197324A0 (en) Synergistic drug combinations for prevention or treatment of glaucoma and ocular hypertension
GB0901727D0 (en) The treatment of ophthalmic diseases
HU0900298D0 (en) Immungenic nanomedicine for the prevention and treatment of allergy
HK1168780A (en) Methods for treating or preventing ophthalmological diseases
IL208831A0 (en) Methods of treating ophthalmic disorders